2021 annual results: strong growth of 20% in income from day-to-day operations and marked improvement in profitability
• Positive gross operating surplus and net income
• Significant increase in services provided for the SeqOIA consortium and the P2M platform operated for the Institut Pasteur
• Limited negative impact of the health crisis throughout the year
• Outlook: continued revenue growth in 2022 based on order backlog
Évry, France, Friday April 29, 2022, 6 p.m. – IntegraGen (FR0010908723 – ALINT – Eligible PEA PME), a company specializing in the decryption of the human genome, which carries out relevant and quickly interpretable analyzes for academic and private laboratories and member of the OncoDNA Group , today announces its audited annual results for the 2021 financial year, the accounts having been approved by the Board of Directors on April 29, 2022.